This GLP-1 receptor agonist study will test the efficacy and safety of liraglutide in the treatment of people with idiopathic Parkinson's (of no known cause). The trial is taking place at the Cedars-Sinai Medical Center, Los Angeles, U.S. and was selected by the Linked Clinical Trials committee and is co-funded by The Cure Parkinson's Trust and the Van Andel Institute.

This single centre, double-blind, placebo-controlled study will enroll 57 participants. Subjects enrolled in the study will be randomised to receive once daily self-administered injections of liraglutide or placebo at the same dose range in a 2:1 study design.

Liraglutide has been approved to treat adults with type 2 diabetes and to treat obesity, but it is considered investigational in this study, as it has not yet been approved for use in people with Parkinson's. Liraglutide belongs to a class of medications able to stimulate receptors of glucagon-like peptide 1 (GLP-1), a naturally occurring peptide found throughout much of the brain and able to increase the gut hormone 'incretin' effect in diabetes stimulating the release of insulin. Liraglutide can reduce systemic and brain insulin resistance, an abnormality that could drive Parkinson's pathogenesis. Indeed, impaired insulin signalling in the brain can cause or exacerbate many brain pathologies and behavioral abnormalities seen in PD. Another GLP-1 agonist, exenatide, has been trialled in people with PD, showing significant improvement of motor and cognitive symptoms. There is reason to believe that liraglutide may prove superior to exenatide in treating PD.

Cedars-Sinai Medical Center is conducting the research study to look at the potential symptomatic and disease modifying effects of liraglutide on the cognitive and motor functions of people with Parkinson’s. Recent evidence from a placebo-controlled clinical trial has found positive clinical outcomes in patients treated with exenatide, a similar medication to liraglutide. The liraglutide study is actively recruiting and this is a great opportunity to be involved in exciting research that will build on existing knowledge established in the recent exenatide trial. For questions or information, please contact Tina Wu in the US at (424) 315-2870 and/or email [email protected]

Eligible participants will be followed for up to 14 months and will be assessed by changes in the MDS-UPDRS and non-motor symptoms after 52 weeks of treatment. 

Source: Fox Trial Finder - The Michael J Fox Foundation Trial 4920